Roche
2023
The pharmaceutical industry is one of Germany’s most important export industries. In recent years, the export of pharmaceutical products has seen above-average growth compared to the other export sectors. In addition, research and development play a prominent role for pharmaceutical companies.
Our new study for Roche focuses on these two aspects. It examines the extent to which the German pharmaceutical industry is particularly value-added intensive and innovative in its exports.
Compared to those in the other industries, German pharmaceutical exports are characterised by above-average value-added intensity and growth dynamics. This means that the export of pharmaceutical products (for example, worth one million euros) is linked to more domestic value added and jobs than the average German export of one million euros.
In an international comparison, the German pharmaceutical industry is shown to be one of the most important players on the world market and has been able to maintain its share of world exports in recent years.
In terms of research, the German pharmaceutical industry is losing ground on its international competitors:
For this detailed investigation of the German pharmaceutical industry in a national and international comparison, we relied on the available statistical data. This was then analysed with the help of the Prognos model landscape.
To the study (PDF in German)
Further information, in German (Roche website)
Project team: Dr Georg Klose, Dr Andreas Sachs, Johann Weiss
Latest update: 07.12.2023
Senior Project Manager
On behalf of the Federal Ministry of Education, Science and Research and the Federal Government Commissioner for Culture and the Media, Prognos and partner analysed the economic and social situation of self-employed solo artists in creative professions.
A shrinking workforce, digitalisation and decarbonisation: Prognos examines the specific effects of global trends on regional labour markets.
Higher numbers of care-dependent persons and increasing costs - our aging population is putting long-term care insurance to the test. A new analysis shows what the future financial require-ments will be.
How effectively do the federal states utilise ERDF funding? Prognos supports various federal states with the evaluation of their ERDF programmes.
How effective is EU support for small and medium-sized enterprises (SMEs) through the European Regional Development Fund (ERDF)? On behalf of the European Commission, Prognos evaluates together with CSIL the ERDF funding in the period from 2014 to 2020.
The skilled-worker shortage is only due to get worse in the future. Our Potential Index shows: Increased digitalisation can help to cushion the negative consequences of the skilled-worker shortage in Germany.
On behalf of the Federal Ministry for Economic Affairs and Climate Action, we calculated the investments that will be required to restructure capital stock in the course of the envisaged net zero transition.
A race to catch up - this is what Europe needs if it is not to be left behind by the USA and China. In the SPIEGEL guest article, Christian Böllhoff calls for a new match plan with clear priorities for the new EU legislative period.
In uncertain times, there is a growing demand for orientation. PEO® delivers independent figures. Based on our wolrd economy model we project the developments until 2045.
Growth in the German economy benefits the whole of Europe. Our study for the vbw shows that this is due to the size of the economy and its strong foreign trade networks.
Prognos is one of the oldest economic research centres in Europe. Founded at the University of Basel, Prognos experts have been conducting research for a wide range of clients from the public and private sectors since 1959 – politically independent, scientifically sound.